Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis

• Published in: Arthritis research & therapy Vol. 12; no. 2; p. R51
• Main Authors: Palomino-Morales, Rogelio J, Vazquez-Rodriguez, Tomas R, Torres, Orlando, Morado, Inmaculada C, Castañeda, Santos, Miranda-Filloy, Jose A, Callejas-Rubio, Jose L, Fernandez-Gutierrez, Benjamin, Gonzalez-Gay, Miguel A, Martin, Javier
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.01.2010; BioMed Central
• Subjects: Biological assay; Biopsy; Development and progression; Drug Therapy, Combination; Genetic polymorphisms; Genetic Predisposition to Disease; Genotype; Giant cell arteritis; Giant Cell Arteritis - drug therapy; Giant Cell Arteritis - genetics; Giant Cell Arteritis - pathology; Humans; Identification and classification; Interleukin-18 - genetics; Interleukin-8; Linkage Disequilibrium; Methods; Methylprednisolone - therapeutic use; Polymerase chain reaction; Polymorphism, Genetic; Prednisone - therapeutic use; Properties; Research article; Toll-Like Receptor 4 - genetics; Spain
• ISSN: 1478-6354; 1478-6362
• DOI: 10.1186/ar2962

The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms in the susceptibility to giant-cell arteritis (GCA). In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C (rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase chain reaction, by using a predesigned TaqMan allele discrimination assay. No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18 -607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95). In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297 C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was 1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an OR of 3.7. Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic variants was observed.